BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Jamjoom Pharma and Magrabi Health Group sign MoU to enhance ophthalmology services in Saudi Arabia

March 30, 2026 | News

Encompassing medical training, health awareness, and the advancement of innovative therapeutic solutions

In a move reflecting their shared commitment to advancing the healthcare sector and elevating the quality of medical services, Jamjoom Pharma, one of the fastest-growing pharmaceutical companies in the Middle East and Africa, has announced the signing of a strategic Memorandum of Understanding (MoU) with Magrabi Health Group.

The agreement aims to enhance cooperation in ophthalmology, encompassing medical training, health awareness, and the advancement of innovative therapeutic solutions.

This partnership aligns with ongoing efforts to unify medical and pharmaceutical expertise. Both institutions strive to deliver an integrated model that improves the quality of healthcare provided to ophthalmology patients across Saudi Arabia and the broader region.

The MoU centres on launching several joint initiatives. Most notably, the partnership will develop specialised training programmes for ophthalmologists and other healthcare practitioners. It will also organise scientific workshops and conferences to upskill medical personnel and ensure they remain aligned with the latest global practices in diagnosis and treatment.

Furthermore, the collaboration includes comprehensive awareness campaigns targeting various community segments. These initiatives aim to educate the public about eye diseases and prevention methods, emphasising the critical importance of early screening for conditions that may develop without clear symptoms, such as glaucoma and retinopathy. This will be achieved through field events, complimentary screenings, and educational content distributed across media and digital platforms.